骨髄増殖性疾患治療薬の市場規模、シェア、動向分析レポート：適応症別、治療タイプ別、最終用途別、地域別、セグメント別予測、2025年～2030年

骨髄増殖性疾患治療薬市場の成長と動向

Grand View Research, Inc.の最新レポートによると、骨髄増殖性疾患治療薬の世界市場規模は、2025～2030年にかけてCAGR 5.9%を記録し、2030年までに158億3,000万米ドルに達すると予測されています。

新薬の入手可能性、強力なパイプラインの存在、ライフスタイルの変化による骨髄増殖性障害の罹患率の上昇、高齢者の増加、社会的認知度の向上などが、同市場の主要成長刺激要因となっています。Jakafi不耐容患者に対するセカンドラインでの治療開発は、Ph-MPN市場に有利に働くと推定されます。

慢性骨髄増殖性疾患は、末梢血や骨髄における成熟骨髄球（赤血球、顆粒球、血小板）やその前駆細胞（骨髄球、メタ骨髄球、有核赤血球、巨核球）の異常蓄積を伴う稀な血液悪性疾患です。この分類の疾患には主に4つの骨髄増殖性疾患があり、フィラデルフィア染色体の有無によってさらに分類されます。

骨髄増殖性疾患は、東アジア諸国に比べて北米と西欧で発生率が高いです。ほとんどの患者は60歳以降にMPNと診断されるが、どの年齢層でも発症する可能性があります。米国は骨髄増殖性疾患治療薬の最も有力な市場であり、その理由は対象人口が多いからです。

骨髄増殖性疾患治療薬市場レポートハイライト

• 北米の骨髄増殖性疾患治療薬市場は、骨髄増殖性疾患の高い有病率と革新的治療をサポートする先進的医療インフラに牽引され、2024年の売上高シェア40.2%で世界市場を席巻しました。
• 強いアンメットニーズが市場の将来を形成し、画期的なファースト・イン・クラスの治療法の開発を促すと考えられます。アンメットニーズが存在するMPNsでは、Jakafiよりも安全性が高く、治癒率が高く、アレルギー作用の少ない薬剤に対するアンメットニーズが存在します。
• 主要市場参入企業は、Novartis、ブリストル・マイヤーズスクイブ、Pfizer、武田薬品工業、洞察、テバなどです。有力企業の主要戦略には、市場開拓のための提携や新興国市場での地域拡大が含まれます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 骨髄増殖性疾患治療薬市場の変数、動向、範囲

• 市場系統の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 産業分析-ポーターのファイブフォース分析
  • PESTLE分析

第4章 骨髄増殖性疾患治療薬市場：適応症ビジネス分析

• 適応症市場シェア、2024年と2030年
• 適応症セグメントダッシュボード
• 市場規模と予測と動向分析、適応症別、2018～2030年
• Ph+慢性骨髄性白血病（CML）
• Ph-骨髄増殖性腫瘍（MPN）

第5章 骨髄増殖性疾患治療薬市場：治療タイプビジネス分析

• 治療タイプ市場シェア、2024年と2030年
• 治療タイプセグメントダッシュボード
• 市場規模と予測と動向分析、治療タイプ別、2018～2030年
• 化学療法
• 標的療法
• その他

第6章 骨髄増殖性疾患治療薬市場：最終用途ビジネス分析

• 最終用途市場シェア、2024年と2030年
• 最終用途セグメントダッシュボード
• 市場規模と予測と動向分析、最終用途別、2018～2030年
• 病院
• 専門クリニック
• その他

第7章 骨髄増殖性疾患治療薬市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 国別、2018～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 国別、2018～2030年
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • デンマーク
  • スウェーデン
• アジア太平洋
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • 国別、2018～2030年
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 国別、2018～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited.
  • Incyte.
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Eli Lilly and Company.
  • GSK plc.
  • GL Pharma

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global myeloproliferative disorders drugs market, by region, 2018 - 2030 (USD Billion)
• Table 4 Global myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 5 Global myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 6 Global myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 7 North America myeloproliferative disorders drugs market, by country, 2018 - 2030 (USD Billion)
• Table 8 North America myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 9 North America myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 10 North America myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 11 U.S. myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 12 U.S. myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 13 U.S. myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 14 Canada myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 15 Canada myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 16 Canada myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 17 Mexico myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 18 Mexico myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 19 Mexico myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 20 Europe myeloproliferative disorders drugs market, by country, 2018 - 2030 (USD Billion)
• Table 21 Europe myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 22 Europe myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 23 Europe myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 24 UK myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 25 UK myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 26 UK myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 27 Germany myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 28 Germany myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 29 Germany myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 30 France myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 31 France myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 32 France myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 33 Italy myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 34 Italy myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 35 Italy myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 36 Spain myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 37 Spain myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 38 Spain myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 39 Norway myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 40 Norway myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 41 Norway myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 42 Denmark myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 43 Denmark myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 44 Denmark myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 45 Sweden myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 46 Sweden myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 47 Sweden myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 48 Asia Pacific myeloproliferative disorders drugs market, by country, 2018 - 2030 (USD Billion)
• Table 49 Asia Pacific myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 50 Asia Pacific myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 51 Asia Pacific myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 52 Japan myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 53 Japan myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 54 Japan myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 55 China myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 56 China myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 57 China myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 58 India myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 59 India myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 60 India myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 61 Australia myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 62 Australia myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 63 Australia myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 64 South Korea myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 65 South Korea myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 66 South Korea myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 67 Thailand myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 68 Thailand myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 69 Thailand myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 70 Latin America myeloproliferative disorders drugs market, by country, 2018 - 2030 (USD Billion)
• Table 71 Latin America myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 72 Latin America myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion
• Table 73 Latin America myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion
• Table 74 Brazil myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 75 Brazil myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 76 Brazil myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 77 Argentina myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 78 Argentina myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 79 Argentina myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 80 Middle East & Africa myeloproliferative disorders drugs market, by country, 2018 - 2030 (USD Billion)
• Table 81 Middle East & Africa myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 82 Middle East & Africa myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 83 Middle East & Africa myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 84 South Africa myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 85 South Africa myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 86 South Africa myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 87 Saudi Arabia myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 88 Saudi Arabia myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 89 Saudi Arabia myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 90 UAE myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 91 UAE myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 92 UAE myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
• Table 93 Kuwait myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
• Table 94 Kuwait myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
• Table 95 Kuwait myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 Myeloproliferative disorders drugs market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Indication outlook (USD Billion)
• Fig. 10 Treatment type outlook (USD Billion)
• Fig. 11 End use outlook (USD Billion)
• Fig. 12 Competitive landscape
• Fig. 13 Myeloproliferative disorders drugs market dynamics
• Fig. 14 Myeloproliferative disorders drugs market: Porter's five forces analysis
• Fig. 15 Myeloproliferative disorders drugs market: PESTLE analysis
• Fig. 16 Myeloproliferative disorders drugs market: Indication segment dashboard
• Fig. 17 Myeloproliferative disorders drugs market: Indication market share analysis, 2024 & 2030
• Fig. 18 Ph+ Chronic myelogenous leukemia (CML) market, 2018 - 2030 (USD Billion)
• Fig. 19 Ph- Myeloproliferative neoplasms (MPNs) market, 2018 - 2030 (USD Billion)
• Fig. 20 Myelofibrosis (MF) market, 2018 - 2030 (USD Billion)
• Fig. 21 Polycythemia vera (PV) market, 2018 - 2030 (USD Billion)
• Fig. 22 Essential thrombocythemia (ET) market, 2018 - 2030 (USD Billion)
• Fig. 23 Myeloproliferative disorders drugs market: Treatment type segment dashboard
• Fig. 24 Myeloproliferative disorders drugs market: Treatment type market share analysis, 2024 & 2030
• Fig. 25 Chemotherapy market, 2018 - 2030 (USD Billion)
• Fig. 26 Targeted therapy market, 2018 - 2030 (USD Billion)
• Fig. 27 Others market, 2018 - 2030 (USD Billion)
• Fig. 28 Myeloproliferative disorders drugs market: End use segment dashboard
• Fig. 29 Myeloproliferative disorders drugs market: End use market share analysis, 2024 & 2030
• Fig. 30 Hospitals market, 2018 - 2030 (USD Billion)
• Fig. 31 Specialty clinics market, 2018 - 2030 (USD Billion)
• Fig. 32 Others market, 2018 - 2030 (USD Billion)
• Fig. 33 Myeloproliferative disorders drugs market revenue, by region
• Fig. 34 Regional marketplace: Key takeaways
• Fig. 35 North America myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 36 U.S. country dynamics
• Fig. 37 U.S. myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 38 Canada country dynamics
• Fig. 39 Canada myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 40 Mexico country dynamics
• Fig. 41 Mexico myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 42 Europe myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 43 UK country dynamics
• Fig. 44 UK myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 45 Germany country dynamics
• Fig. 46 Germany myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 47 France country dynamics
• Fig. 48 France myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 49 Italy country dynamics
• Fig. 50 Italy myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 51 Spain country dynamics
• Fig. 52 Spain myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 53 Norway country dynamics
• Fig. 54 Norway myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 55 Denmark country dynamics
• Fig. 56 Denmark myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion
• Fig. 57 Sweden country dynamics
• Fig. 58 Sweden myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 59 Asia Pacific myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 60 Japan country dynamics
• Fig. 61 Japan myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 62 China country dynamics
• Fig. 63 China myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 64 India country dynamics
• Fig. 65 India myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 66 South Korea country dynamics
• Fig. 67 South Korea myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 68 Australia country dynamics
• Fig. 69 Australia myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 70 Thailand country dynamics
• Fig. 71 Thailand myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 72 Latin America myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 73 Brazil country dynamics
• Fig. 74 Brazil myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 75 Argentina country dynamics
• Fig. 76 Argentina myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 77 MEA myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 78 South Africa country dynamics
• Fig. 79 South Africa myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 80 Saudi Arabia country dynamics
• Fig. 81 Saudi Arabia myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 82 UAE country dynamics
• Fig. 83 UAE myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 84 Kuwait country dynamics
• Fig. 85 Kuwait myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
• Fig. 86 Company categorization
• Fig. 87 Company market position analysis
• Fig. 88 Strategic framework

Myeloproliferative Disorders Drugs Market Growth & Trends:

The global myeloproliferative disorders drugs market size is expected to reach USD 15.83 billion by 2030, registering a CAGR of 5.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. Availability of novel drugs, the presence of a strong pipeline, rising incidence of myeloproliferative disorders due to changing lifestyles, growing geriatric population, and increasing public awareness are some of the primary growth stimulants for the market. Therapeutic development in the second-line setting for Jakafi-intolerant patients is estimated to work in favor of the Ph- MPNs market.

Chronic myeloproliferative disorders are rare hematological malignances that involve the abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow. This class of disorder includes four main myeloproliferative diseases, which are further categorized by the presence of the Philadelphia chromosome.

There is a higher incidence of myeloproliferative disorders in North America and Western Europe as compared to East-Asian countries. Most patients are diagnosed with MPNs after 60 years of age, however, the diseases can occur in any age group. The U.S. will be the most prominent market for myeloproliferative disorders drugs owing to the presence of a large target population.

Myeloproliferative Disorders Drugs Market Report Highlights:

• North America myeloproliferative disorders drugs market dominated the global market with a revenue share of 40.2% in 2024, driven by high prevalence rates of myeloproliferative disorders coupled with advanced healthcare infrastructure that supports innovative treatments.
• Strong unmet needs are likely to shape the future of the market and encourage the development of breakthrough first-in-class therapies. Opportunities remain in the Ph- MPNs setting where there exists an unmet need for a safer drug than Jakafi with higher cure rates and lesser allergic effects
• Some of the key market participants are Novartis, Bristol-Myers Squibb, Pfizer, Takeda, Incyte, and Teva. Primary go-to strategies of prominent players include collaborations for the development and regional expansion in emerging markets.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. Treatment Type
  • 1.2.3. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Myeloproliferative Disorders Drugs Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Myeloproliferative Disorders Drugs Market: Indication Business Analysis

• 4.1. Indication Market Share, 2024 & 2030
• 4.2. Indication Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Billion)
• 4.4. Ph+ Chronic Myelogenous Leukemia (CML)
  • 4.4.1. Ph+ Chronic Myelogenous Leukemia (CML) Market, 2018 - 2030 (USD Billion)
• 4.5. Ph- Myeloproliferative Neoplasms (MPNs)
  • 4.5.1. Ph- Myeloproliferative Neoplasms (MPNs) Market, 2018 - 2030 (USD Billion)
  • 4.5.2. Myelofibrosis (MF)
  • 4.5.3. Myelofibrosis (MF) Market, 2018 - 2030 (USD Billion)
  • 4.5.4. Polycythemia Vera (PV)
  • 4.5.5. Polycythemia Vera (PV) Market, 2018 - 2030 (USD Billion)
  • 4.5.6. Essential Thrombocythemia (ET)
  • 4.5.7. Essential Thrombocythemia (ET) Market, 2018 - 2030 (USD Billion)

Chapter 5. Myeloproliferative Disorders Drugs Market: Treatment Type Business Analysis

• 5.1. Treatment Type Market Share, 2024 & 2030
• 5.2. Treatment Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Treatment Type, 2018 to 2030 (USD Billion)
• 5.4. Chemotherapy
  • 5.4.1. Chemotherapy Market, 2018 - 2030 (USD Billion)
• 5.5. Targeted Therapy
  • 5.5.1. Targeted Therapy Market, 2018 - 2030 (USD Billion)
• 5.6. Others
  • 5.6.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 6. Myeloproliferative Disorders Drugs Market: End Use Business Analysis

• 6.1. End Use Market Share, 2024 & 2030
• 6.2. End Use Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
• 6.4. Hospitals
  • 6.4.1. Hospitals Market, 2018 - 2030 (USD Billion)
• 6.5. Specialty Clinics
  • 6.5.1. Specialty Clinics Market, 2018 - 2030 (USD Billion)
• 6.6. Others
  • 6.6.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 7. Myeloproliferative Disorders Drugs Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. U.S. Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Canada Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Framework
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. Mexico Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.5. Europe
  • 7.5.1. Europe Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. UK Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. Germany Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework
    • 7.5.4.3. Competitive Insights
    • 7.5.4.4. France Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework
    • 7.5.5.3. Competitive Insights
    • 7.5.5.4. Italy Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework
    • 7.5.6.3. Competitive Insights
    • 7.5.6.4. Spain Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.7. Norway
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework
    • 7.5.7.3. Competitive Insights
    • 7.5.7.4. Norway Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.8. Denmark
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework
    • 7.5.8.3. Competitive Insights
    • 7.5.8.4. Denmark Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.9. Sweden
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Regulatory Framework
    • 7.5.9.3. Competitive Insights
    • 7.5.9.4. Sweden Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. Japan Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. China Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. India Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. South Korea Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework
    • 7.6.6.3. Competitive Insights
    • 7.6.6.4. Australia Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Framework
    • 7.6.7.3. Competitive Insights
    • 7.6.7.4. Thailand Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.7. Latin America
  • 7.7.1. Latin America Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. Brazil Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Framework
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Argentina Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.8. MEA
  • 7.8.1. MEA Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. South Africa Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Saudi Arabia Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. UAE Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Regulatory Framework
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. Kuwait Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Novartis AG
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Bristol-Myers Squibb Company
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Pfizer Inc.
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Takeda Pharmaceutical Company Limited.
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Incyte.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Teva Pharmaceutical Industries Ltd.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. AbbVie Inc.
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Eli Lilly and Company.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. GSK plc.
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. GL Pharma
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives